The results of the SCAST study did not demonstrate any benefit on vascular or functional outcomes from lowering blood pressure in patients with acute stroke, but the findings were not definitive. We hope that other ongoing large-scale trials will resolve this area of clinical equipoise.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Adams, H. P. Jr et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Interventional Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 38, 1655–1711 (2007).
Sandset, E. C. et al. on behalf of the SCAST Study Group. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377, 741–750 (2011).
Geeganage, C. M. & Bath, P. M. Relationship between therapeutic changes in blood pressure and outcomes in acute stroke: a metaregression. Hypertension 54, 775–781 (2009).
Hacke, W. et al. for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317–1329 (2008).
Mayer, S. A. et al. for the FAST trial investigators. Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated Factor VII? Stroke 40, 833–840 (2009).
Arima, H. et al. Effects of early intensive blood pressure lowering on haematoma growth in acute intracerebral haemorrhage according to time from onset to treatment: the INTERACT study [Acute stroke: treatment and concepts B; abstract 6]. Cerebrovasc. Dis. 27 (Suppl. 6), 16 (2009).
The ENOS Trial Investigators. Glyceryl trinitrate vs control, and continuing vs stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int. J. Stroke 1, 245–249 (2006).
Delcourt, C. et al. for the INTERACT2 Investigators. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT2). Int. J. Stroke 5, 110–116 (2010).
US NIH. ClincalTrials.gov. Antihypertensive Treatment in Acute Cerebral Hemorrhage-II (ATTACH-II) [online], (2011).
Australian New Zealand Clinical Trials Registry. Enhanced Control of Hypertension and Thrombolysis Stroke Study [online], (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J. Chalmers has been on the speakers bureau and has received research support from Servier. H. Arima declares no competing interests.
Rights and permissions
About this article
Cite this article
Arima, H., Chalmers, J. Blood pressure lowering in acute stroke—scant joy from SCAST. Nat Rev Cardiol 8, 366–368 (2011). https://doi.org/10.1038/nrcardio.2011.61
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2011.61
